Effect of Oral T2 Antigen on Chronic Prostatitis/Chronic Pelvic Pain Syndrome in Mice Model

No abstract is available for this paper.

• Publication year

  2019

• Venue

  Inflammation

• Publication date

  2019-08-19

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10753-019-01072-4PMID 31429013
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Novel Treatment of Experimental Autoimmune Prostatitis by Nanoparticle-Conjugated Autoantigen Peptide T2

  2019cited by this paper
• Oral tolerance:Recent advances on mechanisms and potential applications.

  2018cited by this paper
• Establishment of experimental autoimmune prostatitis model by T2 peptide in aluminium hydroxide adjuvant

  2018cited by this paper
• Establishment of a rat model of chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) induced by immunization with a novel peptide T2.

  2017cited by this paper
• Evaluating the voiding spot assay in mice: a simple method with complex environmental interactions.

  2017cited by this paper
• A novel mouse model of chronic prostatitis/chronic pelvic pain syndrome induced by immunization of special peptide fragment with aluminum hydroxide adjuvant.

  2017cited by this paper
• Therapeutic Intervention for Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS): A Systematic Review and Meta-Analysis

  2012cited by this paper
• The Role of Phenotyping in Chronic Prostatitis/Chronic Pelvic Pain Syndrome

  2011cited by this paper
• Oral tolerance

  2011cited by this paper
• Epidemiology and evaluation of chronic pelvic pain syndrome in men.

  2008cited by this paper
• Mechanisms in prostatitis/chronic pelvic pain syndrome.

  2008cited by this paper
• Physiologic regulation of central and peripheral T cell tolerance: lessons for therapeutic applications

  2006cited by this paper
• Oral Tolerance: Therapeutic Implications for Autoimmune Diseases

  2006cited by this paper
• Therapeutic potential of oral tolerance

  2004cited by this paper
• Mechanisms in prostatitis/chronic pelvic pain syndrome.

  2004cited by this paper
• Oral administration of insulin to neonates suppresses spontaneous and cyclophosphamide induced diabetes in the NOD mouse.

  2001cited by this paper
• Oral tolerance: immune mechanisms and the generation of Th3-type TGF-beta-secreting regulatory cells.

  2001cited by this paper
• Prostatodynia - Pelvic Pain Syndrome

  2001cited by this paper
• Oral tolerance.

  2000cited by this paper
• NIH consensus definition and classification of prostatitis.

  1999cited by this paper
• How common is prostatitis? A national survey of physician visits.

  1998cited by this paper
• Elevated levels of proinflammatory cytokines in the semen of patients with chronic prostatitis/chronic pelvic pain syndrome.

  1998cited by this paper
• Mast cells in accessory glands of experimentally induced prostatitis in male Wistar rats.

  1995cited by this paper
• Suppression of experimental autoimmune myasthenia gravis by oral administration of acetylcholine receptor.

  1993cited by this paper
• Prevention of pristane-induced arthritis by the oral administration of type II collagen.

  1993cited by this paper
• Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering.

  1992cited by this paper
• Transactivation of the transforming growth factor beta 1 (TGF-beta 1) gene by human T lymphotropic virus type 1 tax: a potential mechanism for the increased production of TGF-beta 1 in adult T cell leukemia

  1990cited by this paper
• Inhibition of S-antigen induced experimental autoimmune uveoretinitis by oral induction of tolerance with S-antigen.

  1990cited by this paper
• Suppression of experimental autoimmune encephalomyelitis by the oral administration of myelin basic protein.

  1988cited by this paper
• Expression and secretion of type beta transforming growth factor by activated human macrophages.

  1987cited by this paper
• Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein and its fragments.

  1987cited by this paper
• Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen.

  1986cited by this paper

• 7,8-dihydroxyflavone attenuates NIH IIIA subtype chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) via TrkB/AKT/SIRT3 signaling activation

  2025cites this paper
• Study of Image Processing Method for Chronic Prostatitis-Chronic Pelvic Pain Syndrome (CP/CPPS) Mice Model

  2024influential citation
• Water‐avoidance stress aggravates prostatic inflammation in a murine model of chronic prostatitis

  2024cites this paper
• RETRACTED ARTICLE: Morphological study of chronic prostatitis–chronic pelvic pain syndrome (CP/CPPS) normal modeling dose of T2 peptide in mice

  2022cites this paper
• Effect of thermophilic bacterium HB27 manganese superoxide dismutase in a rat model of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS)

  2021cites this paper
• Application of Bioinformatics Methods to Identify Key Genes and Functions in Chronic Pelvic Pain

  2021cites this paper
• MicroRNA‐155 deficiency attenuates inflammation and oxidative stress in experimental autoimmune prostatitis in a TLR4‐dependent manner

  2020cites this paper
• The effectiveness of Hedyotis diffusa Willd extract in a mouse model of experimental autoimmune prostatitis

  2020cites this paper
• T2 Peptide Represents a Major Autoantigen Epitope in Experimental Autoimmune Prostatitis

  2020cites this paper
• Experimental autoimmune prostatitis: different antigens induction and antigen-specific therapy

  2020cites this paper
• T2 Peptide Represents a Major Autoantigen Epitope in Experimental Autoimmune Prostatitis

  2020cites this paper
• TRPM8 channels: A review of distribution and clinical role.

  2020cites this paper